ABSTRACT: Infectious complications can reduce fracture healing rate. Broad spectrum antibiotics are commonly administered to prevent and treat musculoskeletal infections. Local antibiotics are applied to the wound site to increase therapeutic concentrations without increasing systemic toxicity, however, may hinder local tissue recovery. Rifampin has been shown to eradicate mature Staphylococcal biofilms and its use proven for treating musculoskeletal infections. In this study, a spontaneously healing defect model in a rat was used to investigate the impact rifampin powder has on endogenous bone healing in both a sterile and contaminated wound. No significant differences were identified in bone volume fraction via microcomputed tomography, radiological scoring, or histology between an empty defect and animals that received vancomycin or rifampin powder in a sterile wound. When applied to a contaminated musculoskeletal wound, the rifampin powder had significantly greater bone formation compared to the control, as measured by microcomputed tomography, plain radiology, and histology. In addition, the animals treated with rifampin powder had reduced bacteria, reduced white blood cell count and reduced number of clinical indications of infection. Interestingly, while the vancomycin group still displayed signs of infection via quantitative microbiology, plain radiology, and histology, there was significant bone formation within the defect and reduction of systemic signs of infection. We demonstrated that the use of rifampin powder allows bone to heal in both a sterile and contaminated model of musculoskeletal infection. To our knowledge, this is the first time the direct impact of local antibiotics on bone healing has been investigated. Published 2018. This article is a U.S. Government work and is in the public domain in the USA. J Orthop Res 36:3142-3150, 2018.
Orthopaedic infections, most commonly associated with severe musculoskeletal injuries, can lead to impaired healing, fracture nonunion, and decreased quality of life. 1, 2 Fixation devices commonly used to stabilize and reduce fractures also provide a platform for opportunistic bacteria to attach and colonize, where they begin to form biofilms recalcitrant to host immune systems and antimicrobial activity. Antibiotics are traditionally administered systemically followed by the application of local antimicrobials for high risk patients and to wounds with confirmed musculoskeletal infection. Local therapy provides high concentrations of antibiotics to the wound, an environment where diminished blood supply may inhibit diffusion of circulating antibiotics. Traditional local antimicrobial application involves the off-label use of polymethylmethacrylate (PMMA) as a delivery device, which elutes antibiotics such as vancomycin, tobramycin, and/or gentamicin. 3 Other safe carriers for antibiotic delivery include ceramic-based resorbable bone void fillers, such as calcium phosphate and calcium sulfate cements. [4] [5] [6] [7] Direct placement of antibiotic powder within wounds is an emerging alternative method to traditional delivery devices. When vancomycin powder is used prophylactically in instrumented spinal surgeries, it has shown a fourfold decrease in surgical site infections. 8 However, its use against established, biofilm infections has not been verified clinically. 9 Through in vitro assays and an in vivo model of established musculoskeletal infection, vancomycin, either via PMMA, or powder, had little efficacy against Staphylococcal biofilms. 10 Rifampin, a member of the rifamycin class of antibiotics, has shown exceptional eradication efficacy in vitro and in vivo. [11] [12] [13] Although rifampin's use for reducing Staphylococcal infections is favorable, systemic rifampin can reach hepatotoxic levels if not monitored and PMMA's properties are greatly altered when loaded with rifampin for local application. With the capability to eradicate nearly all bacteria in a preclinical model of musculoskeletal infection, rifampin powder has promising future use. 14 There is concern that local rifampin application can reduce wound recovery and prevent timely fracture healing. Rifampin is highly toxic to osteoblasts, in vitro. Like a number of antibiotics, such as doxycycline, penicillin, and ciprofloxacin, rifampin causes a decrease in viability and alkaline phosphatase activity at 100 mg/cc compared to vancomycin with approximately 50% decrease in viability at 5,000 mg/cc. 15 Of these, only the negative effects of ciprofloxacin on fracture healing has been investigated in a preclinical model. 16 This study will determine if local rifampin powder interrupts normal long bone healing. This study aimed to use a spontaneously healing, segmental defect in both a sterile and contaminated model to evaluate the effect of rifampin powder on bone healing and its role at reducing musculoskeletal infections to allow natural fracture repair. A spontaneously healing plated midshaft defect model in a rat femur was used to evaluate the effect of local antibiotic powder on bone healing (Supplemental Fig. S1 ). Sprague Dawley rats (N ¼ 114, Harlan, Haslett, MI), with an average weight of 351 AE 12 g were randomly separated into two bone healing studies: (A) evaluation of the effect antibiotic powder has on sterile bone healing and (B) evaluation of the bone healing following bacterial eradication using rifampin powder.
METHODS
Evaluation of Antibiotic Powder in a Sterile Bone Healing Wound Animals (N ¼ 90) were premedicated with sustained release buprenorphine. Under general anesthesia, the right hindlimb of each animal was shaved and prepared for sterile surgery. The femoral shaft was exposed through a lateral incision, the periosteum was removed, and a radiolucent plate was affixed to the right femur with six 0.9 mm threaded Kirschner wires (K-wires). A mid-diaphyseal osteotomy (2.58 AE 0.05 mm) was created with a reciprocating saw under continuous irrigation with normal saline. Animals were randomly selected to receive a treatment or left empty as a control (Table 1) . Antibiotic powders (50 mg per animal) were placed within the defect and soft tissue pocket followed by closure of muscle and skin in layers. Animals were recovered in their cage and assessed for pain twice daily for the first 72 h post-operative and weekly. Animals received twice daily cefazolin (5 mg/kg, SC) for the first 72 h to better replicate standard clinical protocol for open fractures. 17 Randomly, the animals were selected for a time point (2, 4, or 8 weeks) at which point they were anesthetized and euthanized with an overdose of pentobarbital (Fatal-Plus 1 , Vortech Pharmaceuticals, Dearborn, MI). The operative femurs were harvested. All samples were fixed in 10% Neutral Buffered Formalin, imaged with plain radiography and microcomputed tomography (mCT) and processed for decalcified histology.
Evaluation of Antibiotic Powder in a Contaminated Bone Healing Wound Animals (N ¼ 24) underwent the same procedure as previously described with the following changes. While under general anesthesia, following creation of the defect and prior to any treatment placement, 10 mg of collagen prewetted with 10 5 colony forming units (CFU) Staphylococcus aureus (UAMS-1, ATCC 49230) was placed into the defect. Twentyfour hours following inoculation, the animals were again anesthetized and the wound was debrided of devitalized soft tissue and irrigated (I&D) with 60 ml normal saline. Animals were randomly selected to receive a treatment or left empty as a control (Table 2) . Vancomycin or rifampin powders were placed within the defect and soft tissue pocket. Tissues were closed in layers and recovered. Animals received twice daily cefazolin (5 mg/kg, SC) injections for the first 72 h postoperatively. After eight weeks, the animals were anesthetized, euthanized, and femurs harvested. Randomly, femurs were either placed in neutral buffered formalin for bone healing analysis by mCT analysis and decalcified histology or processed for bacteria quantification via enumeration.
Microcomputed Tomography (mCT) Femurs were scanned using the VivaCT40 mCT system (Scanco Medical, Bassersdorf, Switzerland), at 70 kVp energy, 114 mA, 8W, with a 10.5 mm voxel size and a 300 ms integration time. The images were converted to 8-bit bitmap files using Image J (National Institutes of Health, Bethesda, MA), and reoriented with DataViewer (BrukerMicroCT, Kontich, Belgium). Regions of interest (ROI) were hand drawn to include the entire bone callus and the natural defect border within the confines of the cut ends (Fig. 1A ). Bookends were defined as the most proximal and distal image slices with no noticeable cortical bone. The defect border encapsulates the volume of the removed bone segment, determined by interpolating the cross-sectional area between the adjacent intact cortices. The total callus border encapsulates all new bone formation within the confines of the ROI bookends. Using CTan (BrukerMicroCT, Kontich, Belgium), a global threshold to segregate bone from non-bone was determined using the Otsu method. 18 ROIs were analyzed for bone volume fraction (bone volume/total volume). 19 
Radiographic Scoring
Plain radiographs were acquired immediately post-operatively to measure defect size and at euthanasia using a cabinet style x-ray (Carestream MS FX Radiographs of the harvested femurs were compiled and sent to three blinded, outside observers (including an orthopaedic surgeon). Radiographs were scored according to their (i) level of bridging across the span of the defect; (ii) amount of bone growth within the defect; and (iii) amount of extracortical growth outside of the defect ( Supplementary  Fig. S2A ). 20, 21 
Histology
Following mCT, the femurs were decalcified with 5% formic acid over 21 days, and processed using an automated enclosed system (Leica ASP300 Tissue Processor, Leica Biosystems, Buffalo Grove, IL) which includes dehydration with increasing concentrations of ethanol, a xylene wash, and paraffin embedding. Longitudinal sections (5 mm) through the plane of the K-wires were made, and stained with Hematoxylin & Eosin (H&E).
Quantitative Microbiology
Following aseptic harvesting of the hind limb, the fixation plate and K-wires are removed from the femurs. Femurs are snap-frozen in liquid nitrogen, pulverized to a fine powder, suspended in sterile normal saline, and vortexed for 3-5 min. Fixation plate and K-wires were suspended in sterile normal saline and sonicated for 15 min to remove adhered bacteria. Bacteria bioburden was quantified by plating serial dilutions of the bone homogenate and implant supernatants onto 5% sheep's blood agar (Remel, Lenexa, KS). CFU was normalized to sample weight. Resistance to rifampin was determined by plating serial dilutions of bacteria recovered from bone samples onto plates coated with 4 mg/ml rifampin.
22
Blood Draws Blood was drawn via the tail vein while the rats were under anesthesia just prior to surgery (for baseline), 24 h postoperatively, and weekly including day of euthanasia for systemic antibiotic concentration, alanine aminotransferase (ALT 
RESULTS

Rifampin Allows for Spontaneous Bone Healing in a Sterile
Wound Placing therapeutic amounts of rifampin powder in a subcritical defect has no impact on native bone healing in a sterile wound. Using mCT analysis, there were no differences between groups within each individual time point. As expected, there was an increase in bone volume fraction, both within the confines of the defect and the total callus, of each group as a function of Total n is the number of animals that received surgery within each group. Outcome measures are the subset of animals within each group that were assessed by the designated outcome measure, plain radiography, mCT and histology, or quantitative microbiology. time (Fig. 1B) . When radiographically evaluated over the course of 8-weeks, there were no significant differences in bone bridging, bone formation, or extracortical bone growth as designated by at least three independent, outside observers (Supplemental Fig. S2B ). Each group showed signs of bone formation after 2 weeks with continual bone formation after 4 and 8 weeks as well (Fig. 2) . Both the empty defect and rifampin treated defects had similar outcomes, with the vancomycin having an oddly increased bone formation at the 4-week time point (Supplemental Fig. S2B ). It is evident from the radiographs that the control bone samples included extracortical bone growth around the fixation wire ends, a feature not as noticeable in either the vancomycin or rifampin groups.
Histology corroborated the radiographic evidence, with the presence of new bone formation within all three groups. After 2 weeks in vivo, there were signs of spindle cells, such as fibroblasts, within and surrounding the defect as well as new bone formation spurring from the cut edge of the defect (Fig. 3) . New bone formation was seen in and surrounding the defect area along with the presence of chondrocytes in the empty, vancomycin, and rifampin groups indicating endochondral bone formation after 4 (images not shown) and 8 weeks (Fig. 4) . There was no evidence of antibiotic powder after 8 weeks within those animals that received antibiotic powder and no signs of inflammation, necrosis, or osteolysis associated with the defect in any of the groups.
One animal (Vancomycin, 8 week) was anesthetized and euthanized 24 h after surgery due to extremely labored breathing and signs of hypoxia regardless of resuscitation measures. All other animals survived without incident.
Rifampin Improves Outcomes When Placed in a Contaminated Wound
Rifampin reduced radiographic indications of infection compared to the control empty and vancomycin group. When assessed morphologically, there was greater bone volume fraction within the defect and total callus within the rifampin group compared to the control group (Fig. 5) . Plain radiographs reveal lucency, osteolysis and pitting around the fixation wires of both the irrigated and debrided (I&D) control and vancomycin groups, indicating the presence of inflammation and bacteria (Fig. 6) . Additionally, there were indications of bone resorption as identified by the reduced cortex around the defect. Serial plain radiographs further identify the extent of morphological change of the control and vancomycin groups and the progressive bone formation within the rifampin group (Supplemental Fig. S3 ). Histology provides further evidence of bacterial presence within both the control and vancomycin groups with large abscesses, necrotic bone, and S. aureus (Fig. 7) . Rifampin, however, showed histological signs of healthy new bone formation.
After 8 weeks, there was reduced bacteria recovered from both bone and hardware in the rifampin group (Fig. 8) , with no indication of rifampin resistance. 
TOPICAL RIFAMPIN ALLOWS FRACTURE HEALING
Additionally, there was a significant difference in the rate of infection between those groups that received rifampin and those that received vancomycin (Fisher's exact, p < 0.05) in both the bone tissue and hardware. Interestingly, while there was recoverable bacteria within the vancomycin group, the white blood cell count was not different compared to the rifampin group (Fig. 9 ). There was a reduced number of clinical signs of infection (redness, swelling, purulence) in the rifampin group compared to the empty control group (Table 3 ). All animals survived the course of the study without incident.
DISCUSSION
Orthopaedic infections, most commonly caused by S. aureus, can have devastating outcomes. Infections are mitigated and treated through both systemic and local antibiotics. Rifampin has been identified to reduce Staphylococcal biofilms in vitro and in vivo compared to the more common locally applied antibiotic vancomycin. 11, 12, 14 Here, locally applied rifampin powder did not significantly reduce endogenous bone healing in a sterile, spontaneously healing segmental defect model. The control, as well as both vancomycin and rifampin, showed similar rates of healing and bone formation across time-points using mCT and radiographic scoring, a method derived from the clinically used Radiographic Union Scale of Tibial fractures (RUST). 24 Histology showed that even though fragments of antibiotic powder were discovered within the defect at two weeks, bone quality of all three groups was similar after 8 weeks in vivo.
When combined with irrigation and debridement (I&D) in a delayed treatment infection model, rifampin significantly reduced bacterial bioburden and improved bone formation within the defect compared to the I&D only empty control. The animals treated with rifampin show no clinical indications of infection, such as purulence or histological bacteria, thus allowing for natural and endogenous bone fracture repair of the femur. To our knowledge, this is the first time that antibiotic powders, like vancomycin and rifampin, have been evaluated in a preclinical model and shown to have no impact on bone formation. [25] [26] [27] Infection, especially in the presence of orthopaedic devices or necrotic bone, increases the probability of mal-or nonunion. 28 The primary goal of fracture reduction is to create a stable union, which may be hindered by the presence of bacteria and inflammation. 29, 30 Systemic antibiotics are often not effective because they do not get to high enough levels at the wound site and increasing doses can cause systemic toxicity. Local antibiotics have proven to be an effective therapy to reduce bacterial bioburden in musculoskeletal injuries due to the high levels of antibiotic that can be obtained locally without causing systemic toxicity. 9 To confirm the reduction of systemic antibiotics, plasma levels of antibiotic were assessed in Part I with this high local therapeutic dose.
14 Briefly, 50 mg vancomycin placed within the wound resulted in a systemic spike at six hours (22.6 mg/ml) which fell to 2.8 mg/ml by 24 h. Vancomycin has no known nephrotoxicity when administered to rodents at 200 mg/kg. 31 Hepatotoxicity is a known risk with rifampin administration due to its induction of cytochrome P450. 32 When 50 mg rifampin was placed in the wound, the maximum rifampin recovered from serum was 4.7 mg/ml at the 6 h time-point. ALT was measured at surgery, 24 h post-operative, and weekly thereafter, revealing no liver damage throughout the course of the study (Supplemental Fig. S4) . Additionally, the dose of either vancomycin or rifampin administered is below what would traditionally be used for therapeutic systemic administration in rat models of infection. 33 It is also imperative to understand if and how an infection and subsequent treatment regimen will affect bone healing and fracture union. First, bacterial infection alone can cause delayed healing by reducing osteoblast number and by increasing inflammation which activates osteoclast driven resorption rate. Additionally, native pluripotent stem cells can lose the ability to differentiate into bone forming osteoblasts after exposure to bacteria. 34 This study revealed a decrease in the rate of boney bridging of the contaminated rifampin group, nearly eradicated of bacteria, compared to the sterile rifampin group, possibly related to a loss of the bone forming progenitor cells due to the initial infection. In addition to the infection itself, particular classes of antibiotics are believed to impact bone healing. 16, 35, 36 Increasing the concentration of tobramycin from 4% to 8% in an antibiotic loaded demineralized bone matrix reduced the healing properties of the matrix in a rat model of bone repair. 37 Rathbone et al. evaluated the toxicities of several antibiotics on human osteoblasts in vitro, revealing that while vancomycin was relatively benign to both viability and alkaline phosphatase production at 5000 mg/ml, antibiotics such as rifampin, fluoroquinolones, and tetracyclines reduced both viability and alkaline phosphatase by >75% at concentrations roughly 50x lower than vancomycin. 15 The direct effect of locally applied antibiotic powder on fracture healing, however, has never been assessed till now.
Rifampin is a more effective biofilm eradicator than vancomycin, making its use for treating established musculoskeletal infections promising. It has the ability to act on cells in a low metabolic or quiescent state, thus increasing its efficacy against biofilms.
11 Part I revealed the utility of rifampin powder for decreasing musculoskeletal bioburden, including its potential for combination application with broad-spectrum antibiotics to decrease the potential of spontaneous resistance.
14 Vancomycin powder, however, has shown encouraging results when used as a prophylactic antibiotic in clinical spinal fusion cases, with no apparent increase in pseudoarthrosis, 38 but its Figure 8 . Colony forming units (CFU) recovered from bone and hardware. Ã , p < 0.01 and ÃÃ , p < 0.0001 using one way ANOVA and Dunnett's post-hoc test of log-transformed data. Data is represented as individual sample data points (dots) and the mean CFU for each group (horizontal line). Horizontal dashed line indicates infection threshold with those samples above deemed infected and those below not reliably infected due to low colony isolation. There are significantly more positively infected samples versus not using Fisher's exact test (CFU>10 3 identified as reliably infected) for both bone and hardware. use within established infections is limited. In a preclinical model of musculoskeletal infection, vancomycin powder reduces bacterial bioburden when applied up to 6 h after inoculation but antimicrobial efficacy is greatly reduced when treatment is delayed up to 24 h. 10 Within the current study, while there were quantifiable bacteria within the bone, as seen by enumeration and histology, other indications of infection within the vancomycin group were sparse. There were fewer WBC within the blood, fewer clinical signs of infection, and the presence of newly formed bone in the radiographs. A poor performer against bacteria biofilms, vancomycin powder may have eradicated planktonic bacteria leaving bacteria within biofilms untouched. Classic bactericidal macrophage response is directed toward an M1 phenotype. Thurlow et al. discovered that bacteria biofilms alter macrophage activity by activating an anti-inflammatory M2 macrophage phenotype rather than the pro-inflammatory M1 phenotype, thus decreasing normal immune response. [39] [40] [41] Additionally, the recent discovery that M2 macrophages increase osteogenesis of mesenchymal stem cells provides evidence for the increase in bone formation within the vancomycin group despite the presence of biofilm. 42, 43 Further investigation toward bone formation co-localized with biofilm is necessary to determine the particular osteoinductive mechanism. This, and its accompanying study, revealed an alternative local antibiotic therapy to combat established orthopaedic infections.
14 To circumvent hurdles associated with drug delivery devices, such as release kinetics, biocompatibility, and degradation, and performing as a platform for further infection, rifampin powder was applied directly to the site of the defect. These findings do have limitations. First, only a single pathogen was used for the contamination study, however, S. aureus is the most common pathogen associated with musculoskeletal infection. Second, all animals were inoculated with bacteria to achieve a robust and consistent infection rather than match clinical infection rates, which can range from 8% to 52% depending on the type and mechanism of injury. [44] [45] [46] While the infection rate is not clinically relevant, by creating a consistent infection, fewer animal numbers can be used while still acquiring meaningful data.
CONCLUSION
Direct application of rifampin powder offers surgeons the opportunity to apply an antibiotic during definitive care of traumatic musculoskeletal injuries. By evaluating the use of rifampin powder in a preclinical model, we have shown that local rifampin application reduces bacterial bioburden while not preventing normal fracture repair. As a currently available drug, rifampin powder can make a rapid translation toward clinical use.
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